Coronary artery disease risk reduction in HIV-infected persons: a comparative analysis

References

• Antiretroviral Therapy Cohort Collaboration [ATCC]. (2010). Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996–2006: Collaborative analysis of 13 HIV cohort studies. Clinical Infectious Disease, 50(10), 1387–1396. doi:10.1086/652283
   PubMed Web of Science ®Google Scholar
• Burkholder, G. A., Tamhane, A. R., Salinas, J. L., Mugavero, M. J., Raper, J. L., Westfall, A. O., … Willig, J. H. (2012). Underutilization of aspirin for primary prevention of cardiovascular disease among HIV-infected patients. Clinical Infectious Disease, 55(11), 1550–1557. doi:10.1093/cid/cis752
   PubMed Web of Science ®Google Scholar
• Busti, A. J., Bain, A. M., Hall, R. G., 2nd, Bedimo, R. G., Leff, R. D., Meek, C., & Mehvar, R. (2008). Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin. Journal of Cardiovascular Pharmacology, 51(6), 605–610. doi:10.1097/FJC.0b013e31817b5b5a
   PubMed Web of Science ®Google Scholar
• Calza, L., Manfredi, R., Colangeli, V., Trapani, F. F., Salvadori, C., Magistrelli, E., … Viale, P. (2013). Two-year treatment with rosuvastatin reduces carotid intima-media thickness in HIV type 1-infected patients receiving highly active antiretroviral therapy with asymptomatic atherosclerosis and moderate cardiovascular risk. AIDS Research Human Retroviruses, 29(3), 547–556. doi:10.1089/aid.2012.0015
   PubMed Web of Science ®Google Scholar
• Currier, J. S., Taylor, A., Boyd, F., Dezii, C. M., Kawabata, H., Burtcel, B., … Hodder, S. (2003). Coronary heart disease in HIV-infected individuals. Journal of Acquired Immune Deficiency Syndrome, 33(4), 506–512. doi: 10.1097/00126334-200308010-00012
   PubMed Web of Science ®Google Scholar
• Deeks, S. G., & Phillips, A. N. (2009). HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ, 338, a3172. doi:10.1136/bmj.a3172
   PubMed Web of Science ®Google Scholar
• Durand, M., Sheehy, O., Baril, J. G., Lelorier, J., & Tremblay, C. L. (2011). Association between HIV infection, antiretroviral therapy, and risk of acute myocardial infarction: A cohort and nested case-control study using Quebec's public health insurance database. Journal of Acquired Immune Deficiency Syndrome, 57(3), 245–253. doi:10.1097/QAI.0b013e31821d33a5
   PubMed Web of Science ®Google Scholar
• Eckard, A. R., Jiang, Y., Debanne, S. M., Funderburg, N. T., & McComsey, G. A. (2014). Effect of 24 weeks of statin therapy on systemic and vascular inflammation in HIV-infected subjects receiving antiretroviral therapy. Journal of Infectious Disease, 209(8), 1156–1164. doi:10.1093/infdis/jiu012
   PubMed Web of Science ®Google Scholar
• Effros, R. B., Fletcher, C. V., Gebo, K., Halter, J. B., Hazzard, W. R., Horne, F. M., … High, K. P. (2008). Aging and infectious diseases: Workshop on HIV infection and aging: What is known and future research directions. Clinical Infectious Disease, 47(4), 542–553. doi:10.1086/590150
   PubMed Web of Science ®Google Scholar
• Fichtenbaum, C. J., Gerber, J. G., Rosenkranz, S. L., Segal, Y., Aberg, J. A., Blaschke, T., … Aweeka, F. (2002). Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS, 16(4), 569–577. doi: 10.1097/00002030-200203080-00008
   PubMed Web of Science ®Google Scholar
• Freiberg, M. S., Chang, C. C., Kuller, L. H., Skanderson, M., Lowy, E., Kraemer, K. L., … Justice, A. C. (2013). HIV infection and the risk of acute myocardial infarction. JAMA Internal Medicine, 173(8), 614–622. doi:10.1001/jamainternmed.2013.3728
   PubMed Web of Science ®Google Scholar
• Friis-Moller, N., Thiebaut, R., Reiss, P., Weber, R., Monforte, A. D., De Wit, S., … D:A:D Study Group. (2010). Predicting the risk of coronary artery disease in HIV-infected patients: The data collection on adverse effects of anti-HIV drugs study. European Journal of Cardiovascuar Prevention Rehabilitation, 17(5), 491–501. doi:10.1097/HJR.0b013e328336a150
   PubMed Web of Science ®Google Scholar
• Fultz, S. L., Goulet, J. L., Weissman, S., Rimland, D., Leaf, D., Gibert, C., … Justice, A. C. (2005). Differences between infectious diseases-certified physicians and general medicine-certified physicians in the level of comfort with providing primary care to patients. Clinical Infectious Disease, 41(5), 738–743. doi:10.1086/432621
   PubMed Web of Science ®Google Scholar
• Gillespie, C. D., Wigington, C., & Hong, Y. (2013). Coronary heart disease and stroke deaths – United States, 2009. MMWR Surveillance Summaries, 62(Suppl. 3), 157–160.
   PubMed Web of Science ®Google Scholar
• Hsue, P. Y., Deeks, S. G., & Hunt, P. W. (2012). Immunologic basis of cardiovascular disease in HIV-infected adults. Journal of Infectious Disease, 205(Suppl. 3), S375– S382. doi:10.1093/infdis/jis200
   Web of Science ®Google Scholar
• Hsue, P. Y., Hunt, P. W., Schnell, A., Kalapus, S. C., Hoh, R., Ganz, P., … Deeks, S. G. (2009). Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS, 23(9), 1059–1067. doi:10.1097/QAD.0b013e32832b514b
   PubMed Web of Science ®Google Scholar
• Hsyu, P. H., Schultz-Smith, M. D., Lillibridge, J. H., Lewis, R. H., & Kerr, B. M. (2001). Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin. Antimicrobial Agents and Chemotherapy, 45(12), 3445–3450. doi:10.1128/AAC.45.12.3445–3450.2001
   PubMed Web of Science ®Google Scholar
• Justice, A. C., & Braithwaite, R. S. (2012). Lessons learned from the first wave of aging with HIV. AIDS, 26(Suppl. 1), S11–18. doi:10.1097/QAD.0b013e3283558500
   Google Scholar
• Kaplan, R. C., Sinclair, E., Landay, A. L., Lurain, N., Sharrett, A. R., Gange, S. J., … Hodis, H. N. (2011). T cell activation predicts carotid artery stiffness among HIV-infected women. Atherosclerosis, 217(1), 207–213. doi:10.1016/j.atherosclerosis.2011.03.011
   PubMed Web of Science ®Google Scholar
• Klein, D., Hurley, L. B., Quesenberry, C. P. Jr., & Sidney, S. (2002). Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? Journal of Acquired Immune Deficiency Syndrome, 30(5), 471–477. doi: 10.1097/00126334-200208150-00002
   PubMed Web of Science ®Google Scholar
• Landon, B. E., Wilson, I. B., McInnes, K., Landrum, M. B., Hirschorn, L. R., Marsden, R. V., & Cleary, P. D. (2005). Physician specialization and the quality of care for human immunodeficiency virus infection. Archives of Internal Medicine, 165(10), 1133–1139. doi: 10.1001/archinte.165.10.1133
   PubMed Web of Science ®Google Scholar
• Lichtenstein, K. A., Armon, C., Buchacz, K., Chmiel, J. S., Buckner, K., Tedaldi, E., … Brooks, J. T. (2013). Provider compliance with guidelines for management of cardiovascular risk in HIV-infected patients. Preventing Chronical Disease, 10, E10. doi:10.5888/pcd10.120083
   Google Scholar
• Marin, B., Thiebaut, R., Bucher, H. C., Rondeau, V., Costagliola, D., Dorrucci, M., … Chene, G. (2009). Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. AIDS, 23(13), 1743–1753. doi:10.1097/QAD.0b013e32832e9b78
   PubMed Web of Science ®Google Scholar
• Mills, E. J., Barnighausen, T., & Negin, J. (2012). HIV and aging – Preparing for the challenges ahead. New England Journal of Medicine, 366(14), 1270–1273. doi:10.1056/NEJMp1113643
   PubMed Web of Science ®Google Scholar
• Mocroft, A., Reiss, P., Gasiorowski, J., Ledergerber, B., Kowalska, J., Chiesi, A., … EuroSIDA Study Group (2010). Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. Journal of Acquired Immune Deficiency Syndrome, 55(2), 262–270. doi:10.1097/QAI.0b013e3181e9be6b
   PubMed Web of Science ®Google Scholar
• O'Brien, M., Montenont, E., Hu, L., Nardi, M. A., Valdes, V., Merolla, M., … Berger, J. S. (2013). Aspirin attenuates platelet activation and immune activation in HIV-1-infected subjects on antiretroviral therapy: A pilot study. Journal of Acquired Immune Deficiency Syndrome, 63(3), 280–288. doi:10.1097/QAI.0b013e31828a292c
   PubMed Web of Science ®Google Scholar
• Obel, N., Thomsen, H. F., Kronborg, G., Larsen, C. S., Hildebrandt, P. R., Sorensen, H. T., & Gerstoft, J. (2007). Ischemic heart disease in HIV-infected and HIV-uninfected individuals: A population-based cohort study. Clinical Infectious Disease, 44(12), 1625–1631. doi:10.1086/518285
   PubMed Web of Science ®Google Scholar
• Oliviero, U., Bonadies, G., Apuzzi, V., Foggia, M., Bosso, G., Nappa, S., … Sacca, L. (2009). Human immunodeficiency virus per se exerts atherogenic effects. Atherosclerosis, 204(2), 586–589. doi:10.1016/j.atherosclerosis.2008.10.012
   PubMed Web of Science ®Google Scholar
• Palella, F. J. Jr., Baker, R. K., Moorman, A. C., Chmiel, J. S., Wood, K. C., Brooks, J. T., … HIV Outpatient Study Investigators. (2006). Mortality in the highly active antiretroviral therapy era: Changing causes of death and disease in the HIV outpatient study. Journal of Acquired Immune Deficiency Syndrome, 43(1), 27–34. doi: 10.1097/01.qai.0000233310.90484.16
   PubMed Web of Science ®Google Scholar
• Rabkin, M., Kruk, M. E., & El-Sadr, W. M. (2012). HIV, aging and continuity care: Strengthening health systems to support services for noncommunicable diseases in low-income countries. AIDS, 26(Suppl. 1), S77– S83. doi:10.1097/QAD.0b013e3283558430
   Google Scholar
• Seshasai, S. R., Wijesuriya, S., Sivakumaran, R., Nethercott, S., Erqou, S., Sattar, N., & Ray, K. K. (2012). Effect of aspirin on vascular and nonvascular outcomes: Meta-analysis of randomized controlled trials. Archives of Internal Medicine, 172(3), 209–216. doi:10.1001/archinternmed.2011.628
   PubMed Web of Science ®Google Scholar
• Steyerberg, E. W., Eijkemans, M. J., Van Houwelingen, J. C., Lee, K. L., & Habbema, J. D. (2000). Prognostic models based on literature and individual patient data in logistic regression analysis. Statistics in Medicine, 19(2), 141–160. doi: 10.1002/(SICI)1097-0258(20000130)19:2<141::AID-SIM334>3.0.CO;2-O
   PubMed Web of Science ®Google Scholar
• Stone, N. J., Robinson, J., Lichtenstein, A. H., Merz, C. N., Blum, C. B., Eckel, R. H., … Wilson, P. W. (2013). 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American college of cardiology/American heart association task force on practice guidelines. Circulation. doi:10.1161/01.cir.0000437738.63853.7a
   Google Scholar
• Triant, V. A., Lee, H., Hadigan, C., & Grinspoon, S. K. (2007). Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. Journal of Clinical Endocrinology Metabolism, 92(7), 2506–2512. doi:10.1210/jc.2006-2190
   PubMed Web of Science ®Google Scholar
• Wilson, P. W., D'Agostino, R. B., Levy, D., Belanger, A. M., Silbershatz, H., & Kannel, W. B. (1998). Prediction of coronary heart disease using risk factor categories. Circulation, 97(18), 1837–1847. doi: 10.1161/01.CIR.97.18.1837
   PubMed Web of Science ®Google Scholar
• Wolff, T., Miller, T., & Ko, S. (2009). Aspirin for the primary prevention of cardiovascular events: An update of the evidence for the U.S. Preventive Services Task Force. Annals of Internal Medicine, 150(6), 405–410. doi: 10.7326/0003-4819-150-6-200903170-00009
   PubMed Web of Science ®Google Scholar